Back to top
more

Taysha Gene Therapies (TSHA)

(Delayed Data from NSDQ)

$2.79 USD

2.79
2,187,351

+0.05 (1.82%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $2.79 0.00 (0.00%) 6:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 0% and 9.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 41.79% and 21.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Personalis (PSNL) delivered earnings and revenue surprises of 21.74% and 18.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 12.50% and 6.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -20.18% and 10.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -12.50% and 4.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 16.50% and 54.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Personalis (PSNL) delivered earnings and revenue surprises of -93.94% and 24.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 10% and 69.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inotiv (NOTV) delivered earnings and revenue surprises of -122.22% and 14.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Personalis (PSNL) delivered earnings and revenue surprises of 29.41% and 14.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?